57results about How to "Alter metabolism" patented technology

The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and / or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and / or treat diabetes as well as prevent and / or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity.

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists / partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

The present invention concerns the use of methods and compositions to provide an improved lipid:emodin formulation for the treatment of leukemias expressing bcr-abl and other cancer with elevated tyrosine kinase activity.

An apheresis method that includes drawing blood from a mammal, adding an amount of an agent effective in preventing coagulation, wherein the agent is an anticoagulant, extracting one or more constituent components from the blood, wherein an extracted blood and constituent component result therefrom, and diminishing the activity of said anticoagulant by introducing an antidote, wherein the amount of antidote introduced is coupled with the amount of anticoagulant added. The antidote is provided either to the processed blood prior to reintroduction to the donor or directly to the donor. The invention also includes an apheresis machine that includes an antidote delivery conduit, wherein the antidote delivery conduit delivers an amount of antidote that is coupled with an amount of anticoagulant delivered.

The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and / or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid β peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, α-synclein, prion protein, tau and superoxide dismutase 1 (SOD1).

Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and / or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardiovascular disorders and cancer are described. The compositions and methods are effective at decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of non-selective carboxylate-containing-nonsteroidal anti-inflammatory drugs.

The subject invention provides a process and apparatus for making “enhanced water” that is uniquely suitable for improving circulation, hydration and insulin usage with diabetics. Thus, in a preferred embodiment, the invention provides methods for the treatment and / or prevention of diabetes as well as the prevention or delay in development of diabetes-related complications, conditions or diseases.

A method and apparatus that associate a new parenteral injection of medical grade carbon dioxide concomitantly with the application of infrared radiation from thermal and / or light sources using control by means of cutaneous and / or body thermometry, associating the concomitant application of infrared radiation from different light or thermal sources, to the direct injections of medical grade carbon dioxide CO2 into parenteral routes via carbon dioxide infusion regulating apparatuses and infrared radiation emitting apparatuses controlled by cutaneous and / or body thermometry, either direct or indirect.

Novel compositions of silicon-containing sulfhydryl compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative sulfhydryl compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and / or pharmacokinetics. The organosilyl group provides compounds having improved pharmacokinetics. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

An enzymatically produced soluble α-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble α-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble α-glucan fiber are also provided.

An enzymatically produced soluble α-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble α-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble α-glucan fiber are also provided.

The modified human PP peptides (i) [Lys4,Leu17,Ser30,Gln34]hPP, (ii) Lys4,Leu17,Thr30,Gln34]hPP; and (iii) [Lys4,Leu17,oxidised Met30,Gln34]hPP wherein “oxidised Met” may be the sulfoxide or sulfone, and certain analogues and derivativatised forms thereof as referred to in the specification, are selective agonists of the Y2 receptor relative to the Y1 and Y4 receptors, and are useful for, for example, appetite control and therapeutic angiogenesis.

An enzymatically produced soluble α-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble α-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble α-glucan fiber are also provided.

An enzymatically produced soluble α-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble α-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble α-glucan fiber are also provided.

The invention provides seed and plants of sweet corn hybrid SV1446SD and the parent lines thereof. The invention thus relates to the plants, seeds and tissue cultures of sweet corn hybrid SV1446SD and the parent lines thereof, and to methods for producing a sweet corn plant produced by crossing such plants with themselves or with another sweet corn plant, such as a plant of another genotype. The invention further relates to seeds and plants produced by such crossing. The invention further relates to parts of such plants, including the parts of such plants.

The present invention provides promoters from plants capable of driving gene expression in plant cells. The promoters vary in strength and in tissue specificity, and can be used to facilitate the development of transgenic plants in which tissue preferred expression, constitutive expression, and the strength of transgene expression is either more or less critical.

An enzymatically produced soluble α-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble α-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble α-glucan fiber are also provided.

The present invention relates to a recombinant yeast cell comprising a gene encoding a protein exhibiting lactyl-CoA synthase activity and a gene encoding a protein exhibiting lactyl-CoA polymerase activity, said recombinant cell having the ability of producing polylactic acid (PLA), and the uses thereof.

The invention belongs to the field of biological medicine and particularly relates to 1,3,4-selenadiazole compound with drug activity. As a few types of heterocyclic selenium exist and BPTES (thiadiazole compounds) has a strong tumor growth suppressing function, a novel synthesizing method is utilized to synthesize multi functional groups substitutional selenadiazole compound, tests verify that the compound has a tumor inhibition effect, an antioxidation effect and a cell protection function; selenadiazole can serve as bioisostere of thiadiazole to substitute; presently, many drugs contain thiadiazole, so that synthesizing selenadiazole derivative with multi functional groups and further optimizing the activity of the medicinal thiadiazole compound have significance in aspects of new medicine development and application and the like.

The invention relates to a preparation method of 3,5-cynarin methyl ester shown in a formula (1) as well as a medicament composition for preventing influenza and hepatitis. The preparation method comprises the following steps of: preparing 3,5-cynarin methyl ester as well as a medicament composition for preventing influenza and hepatitis by means of semisynthesis by using an extract of one or more of plants such as the composite family, Caprifoliaceae and the like as an intermediate. According to the preparation method of the 3,5-cynarin methyl ester, the 3,5-cynarin methyl ester with high purity can be massively produced from the plants with extremely-low content of the 3,5-cynarin methyl ester.

Glycerol-3-phosphate acyltransferase is the initial enzyme of the glycerolipid biosynthetic pathway. Biochemical analyses indicated that the reaction mediated by glycerol-3-phosphate acyltransferase represents a potential rate-limiting step for the synthesis of phospholipids and storage neutralipid, triacylglycerol. The present invention relates to the cloning of genes encoding extraplastidic membrane-bound glycerol-3-phosphate acyltransferases. Heterologous expression of the genes, GPAT1, GPAT2, and GPAT3 in a yeast glycerol-3-phosphate acyltransferase mutant demonstrated that the encoded products could efficiently utilize glycerol-3-phosphate to mediate sn-1 stereo-specific fatty acid acylation. The invention encompasses the glycerol-3-phosphate acyltransferase peptides disclosed and fragments and homologues thereof, the corresponding gene sequences and fragments and homologues thereof, as well as the use of the peptide and gene sequences of the present invention for use in generating recombinant proteins, and transgenic plants with altered lipid metabolism. In this way, the present invention also encompasses the use of such recombinant peptides and transgenic plants for the production of lipid products for use, for example, in pharmaceutical and nutritional applications.

The invention relates to application of N-(3- pyridine formex oxygen radical)-3, 5- dimethyl-1- amantadine or pharmaceutically-acceptable salt for treating vascular dementia.

The invention provides a method to identify a plurality of plant promoters having specified characteristics and promoters identified by the method. Also provided are transgenic plants comprising the genes identified by the methods of the invention.

Disclosed is an anticancer prodrug that disturbs energy metabolism in cancer cells to overcome drug resistance. The anticancer prodrug has a structure including a pyruvate dehydrogenase kinase (PDK) inhibitor moiety, a mitochondrial targeting group, and an anthracycline moiety reversibly connected to the PDK inhibitor moiety and the targeting group.

The present invention relates to a recombinant yeast cell comprising a gene encoding a protein exhibiting lactyl-CoA synthase activity and a gene encoding a protein exhibiting lactyl-CoA polymerase activity, said recombinant cell having the ability of producing polylactic acid (PLA), and the uses thereof.

An artificially recombined engineering polypeptide resisting against staphylococei is composed of the staphylococcus' signal transfer polypeptide and the colicin able to form ion channel or its water pore canal structure domain. Its preparing process includes using point mutation to insert the staphylococcus' signal transfer polypeptide gene into the site chosen by colicin gene loaded in engineering plasmid and transfecting the mutative plasmid to engineering bacteria. Its advantages are strong antibacterial power to staphylococei, and not generating resistance easily by staphylococei.

The instant invention is directed to a constitutive promoter for use in plants. The plant genus from which the promoter is derived is Arabidopsis. The invention encompasses the isolated promoter, expression cassettes comprising said promoter and a heterologous nucleic acid segment, and monocot and dicot plants and plant cells transformed with said expression cassettes.